EGFR and non-small cell lung carcinoma: For example, in a trial to study gefitinib for EGFR-mutant non-small cell lung cancer, one of the trial eligibility criteria would be “An EGFR sensitizing mutation must be detected in tumor tissue.”22 The second type of clinical text is clinical notes documented in EHRs.